

Corey S Cutler

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1786416/corey-s-cutler-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

261
papers

17,596
citations

69
h-index

130
g-index

278
ext. papers

20,724
ext. citations

4.4
avg, IF

5.96
L-index

#	Paper	IF	Citations
261	Yin and Yang of Psychological Health in the Cancer Experience: Does Positive Psychology Have a Role?. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102507	2.2	0
260	A Review of Oral Chronic Graft-Versus-Host Disease: Considerations for dental hygiene practice.. <i>Journal of Dental Hygiene: JDH / American Dental Hygienists Association</i> , 2022 , 96, 6-17	1.1	
259	Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease. <i>Blood</i> , 2021 , 138, 264-264	2.2	0
258	Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease. <i>Blood</i> , 2021 , 138, 2891-2891	2.2	
257	Topical sirolimus for management of refractory oral chronic graft-versus-host disease. <i>Oral Diseases</i> , 2021 , 27, 1451-1454	3.5	0
256	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 452-466		7
255	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2108-2117	4.4	1
254	A positive psychology intervention to promote health outcomes in hematopoietic stem cell transplantation: the PATH proof-of-concept trial. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2276-2279	4.4	3
253	The clinical and functional effects of TERT variants in myelodysplastic syndrome. <i>Blood</i> , 2021 , 138, 898-911	4.1	4
252	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3328-3339	2.2	14
251	Treating Inflammation and Fibrosis in Chronic GVHD: Two Birds, One ROCK. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1942-1945	2.2	
250	Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. <i>Blood</i> , 2021 , 138, 2278-2289	2.2	24
249	Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. <i>Leukemia</i> , 2021 , 35, 1166-1175	10.7	2
248	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1006-1012	4.4	5
247	Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2021 , 5, 352-364	7.8	15
246	COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. <i>Blood Advances</i> , 2021 , 5, 861-871	7.8	11
245	Use of Prescription Sialagogues for Management of Xerostomia in Chronic Graft-versus-Host-Disease. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 480.e1-480.e5		1

244	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. <i>Blood Advances</i> , 2021 , 5, 975-983	7.8	5
243	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021 , 137, 3212-3217	2.2	9
242	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 545-557		15
241	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. <i>Haematologica</i> , 2021 , 106, 3219-3222	6.6	7
240	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 632-641		6
239	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 729-737		5
238	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021 , 5, 4549-4559	7.8	1
237	Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. <i>Blood Advances</i> , 2021 , 5, 5140-5149	7.8	2
236	Disseminated varicella-zoster virus infections following messenger RNA-based COVID-19 vaccination. <i>JAAD Case Reports</i> , 2021 , 17, 126-129	1.4	1
235	Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. <i>Blood Advances</i> , 2021 , 5, 4278-4284	7.8	2
234	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 817-835		5
233	In response to "American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults". <i>Blood Advances</i> , 2020 , 4, 5431-5432	7.8	1
232	Oral health in allogeneic hematopoietic stem cells transplantation survivors. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2211-2214	4.4	1
231	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020 , 135, 2182-2191	2.2	31
230	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020 , 4, 1965-1973	7.8	23
229	BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020 , 4, 1881-1893	7.8	7
228	Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab. <i>Blood</i> , 2020 , 136, 10-11	2.2	
227	Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2020 , 136, 2-3	2.2	

226	Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2020 , 130, 4624-4636	15.9	18
225	Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213). <i>Blood</i> , 2020 , 136, 45-46	2.2	7
224	Disability Related to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 772-777	4.7	9
223	Incidence, Predictors, and Outcomes of Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 529-539	4.7	7
222	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. <i>JAMA Oncology</i> , 2020 , 6, 486-493	13.4	19
221	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020 , 4, 3180-3190	7.8	4
220	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. <i>Blood Advances</i> , 2020 , 4, 4113-4123	7.8	13
219	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. <i>Blood</i> , 2020 , 136, 3070-3081	2.2	13
218	Long-Term Utilization Patterns of Topical Therapy and Clinical Outcomes of Oral Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 373-379	4.7	2
217	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. <i>Blood</i> , 2020 , 135, 28-40	2.2	8
216	Early Clinical Predictors of Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 137-144	4.7	27
215	The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2468-2473	4.7	4
214	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4 and CD8 T effector memory cells and increase of T regulatory cells. <i>Clinical Immunology</i> , 2019 , 207, 18-23	9	4
213	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2002-2007	4.7	32
212	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402). <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2143-2151	4.7	11
211	Targeting PI3K function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019 , 19, 1820-1830	8.7	8
210	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. <i>Blood Advances</i> , 2019 , 3, 2550-2561	7.8	19
209	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019 , 3, 1826-1836	7.8	50

208	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019 , 3, 2199-2204	7.8	24
207	Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2019 , 3, 4136-4146	7.8	17
206	Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. <i>Blood Advances</i> , 2019 , 3, 969-979	7.8	15
205	The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 279-286	4.7	4
204	Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 451-458	4.7	10
203	Machine learning reveals chronic graft-host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies. <i>Haematologica</i> , 2019 , 104, 189-196	6.6	33
202	Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 599-605	4.7	15
201	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2019 , 133, 94-99	2.2	14
200	Economic and Practical Considerations in the Treatment of Oral Mucosal Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1748-1753	4.7	6
199	Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. <i>Blood</i> , 2018 , 131, 1372-1379	2.2	59
198	Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 393-399	4.7	17
197	A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-host disease: BMT CTN 0801. <i>Haematologica</i> , 2018 , 103, 1915-1924	6.6	21
196	Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2344-2353	4.7	19
195	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem-Cell Transplantation: A Post-Hoc Analysis of a Randomized Controlled Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate (BMT CTN 0402). <i>Blood</i> , 2018 , 132, 2110-2110	2.2	1
194	A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Blood</i> , 2018 , 132, 705-705	2.2	9
193	Incidence and Predictors of Hepatic Veno-Occlusive Disease after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018 , 132, 3376-3376	2.2	
192	Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2018 , 132, 817-817	2.2	
191	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018 , 2, 1882-1888	7.8	16

190	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. <i>Blood Advances</i> , 2018 , 2, 1022-1031	7.8	8
189	Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2164-2165	4.7	3
188	Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 882-896	4.7	77
187	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017 , 129, 2186-2197	2.2	109
186	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017 , 376, 536-547	59.2	383
185	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017 , 129, 1753-1762	2.2	189
184	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017 , 130, 360-367	2.2	39
183	A multicenter, retrospective, case-cohort study of the epidemiology and risk factors for <i>Clostridium difficile</i> infection among cord blood transplant recipients. <i>Transplant Infectious Disease</i> , 2017 , 19, e12728	2.7	10
182	Venous thromboembolism is associated with graft--host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017 , 102, 1185-1191	6.6	18
181	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 971-979	4.7	11
180	Improved survival after acute graft--host disease diagnosis in the modern era. <i>Haematologica</i> , 2017 , 102, 958-966	6.6	50
179	Mechanistic approaches for the prevention and treatment of chronic GVHD. <i>Blood</i> , 2017 , 129, 22-29	2.2	68
178	Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. <i>Blood</i> , 2017 , 129, 162-170	2.2	56
177	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. <i>Cytotherapy</i> , 2017 , 19, 272-284	4.8	13
176	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017 , 130, 2243-2250	2.2	220
175	Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. <i>Blood</i> , 2017 , 130, 2889-2899	2.2	13
174	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 126-133	4.7	9
173	Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 103-112	4.7	3

172	Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. <i>Blood Advances</i> , 2017 , 1, 2269-2279	7.8	15
171	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. <i>JCI Insight</i> , 2017 , 2,	9.9	40
170	Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 1583-1589	13.4	78
169	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. <i>Blood</i> , 2016 , 127, 2489-97	2.2	71
168	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2016 , 375, 143-53	59.2	365
167	Biomarker Panel for Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2583-90	2.2	88
166	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 449-55	4.7	71
165	Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 910-8	4.7	19
164	Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402. <i>Blood</i> , 2016 , 128, 63-63	2.2	
163	Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation: A Phase II Randomized Controlled Trial. <i>Blood</i> , 2016 , 128, 508-508	2.2	
162	BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016 , 128, 3425-3425	2.2	
161	Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease. <i>Blood</i> , 2016 , 128, 667-667	2.2	
160	Low-dose IL-2 selectively activates subsets of CD4 Tregs and NK cells. <i>JCI Insight</i> , 2016 , 1, e89278	9.9	87
159	The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. <i>British Journal of Haematology</i> , 2016 , 173, 96-104	4.5	43
158	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016 , 122, 3005-3014	6.4	32
157	A novel TERC CR4/CR5 domain mutation causes telomere disease via decreased TERT binding. <i>Blood</i> , 2016 , 128, 2089-2092	2.2	4
156	Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016 , 101, 499-505	6.6	26
155	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016 , 128, 2350-2358	2.2	33

154	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. <i>Blood</i> , 2016 , 127, 2144-54	2.2	94
153	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1864-71	2.2	46
152	Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. <i>Blood</i> , 2016 , 127, 646-57	2.2	109
151	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. <i>Blood</i> , 2016 , 128, 130-7	2.2	132
150	An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2084-2091	4.7	8
149	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2016 , 101, 1251-1259	6.6	17
148	Manifestations and Treatment of Acute Graft-versus-Host Disease 2016 , 1012-1025		5
147	Mammalian target of rapamycin inhibitor-associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 503-8	4.7	13
146	A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1907-13	4.7	25
145	Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 873-80	4.7	38
144	Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 640-5	4.7	21
143	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1343-59	4.7	69
142	Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 266-74	4.7	214
141	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 389-401.e1	4.7	1187
140	B cells in chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 16-23.4.7		63
139	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015 , 125, 4085-94	2.2	76
138	Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. <i>Haematologica</i> , 2015 , 100, 1222-7	6.6	13
137	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1776-82	4.7	11

136	Reprint of: B cells in chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, S11-8	4.7	4
135	Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age. <i>Blood</i> , 2015 , 126, 193-193	2.2	10
134	Outcomes of Grades II-IV Acute Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: How Much Progress Was Achieved?. <i>Blood</i> , 2015 , 126, 3132-3132	2.2	1
133	IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. <i>PLoS ONE</i> , 2015 , 10, e0132564	3.7	15
132	Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD). <i>Blood</i> , 2015 , 126, 1930-1930	2.2	
131	Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trial Network #1102 study. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1262-73	4.7	18
130	A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1737-43	4.7	37
129	Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 668-75	4.7	29
128	Outcomes and management strategies for graft failure after umbilical cord blood transplantation. <i>American Journal of Hematology</i> , 2014 , 89, 1097-101	7.1	9
127	Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1262-73	4.7	130
126	Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 202-8	4.7	27
125	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014 , 123, 3988-98	2.2	144
124	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. <i>Blood</i> , 2014 , 124, 1372-7	2.2	142
123	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014 , 124, 4867-76	15.9	132
122	Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 77-81	3.1	6
121	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014 , 99, 1499-508	6.6	14
120	Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2691-8	2.2	295
119	Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 804-11	4.7	10

118	Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2662-70	2.2	203
117	Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. <i>Science Translational Medicine</i> , 2013 , 5, 179ra43	17.5	312
116	Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. <i>Blood</i> , 2013 , 122, 3074-81	2.2	252
115	Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). <i>Blood</i> , 2013 , 122, 1974-82	2.2	69
114	Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. <i>Blood</i> , 2013 , 122, 1510-7	2.2	93
113	Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients. <i>Blood</i> , 2013 , 122, 695-695	2.2	1
112	Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intensity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis. <i>Blood</i> , 2013 , 122, 2093-2093	2.2	
111	Reconstitution Of EBV-Specific Immunity In Adult Recipients Of Double Cord Blood Transplantation Depends On SCF and IL-7 Levels and Maintenance Of a Diverse TCR Repertoire. <i>Blood</i> , 2013 , 122, 3302-3302	2.2	
110	A disease risk index for patients undergoing allogeneic stem cell transplantation. <i>Blood</i> , 2012 , 120, 905-13	2.2	259
109	Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. <i>Blood</i> , 2012 , 120, 2545-52; quiz 2774	2.2	91
108	Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1649-55	4.7	21
107	Transplantation for MDS in the elderly: more evidence, or more bias?. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1320-1	4.7	5
106	B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. <i>Blood</i> , 2012 , 120, 2529-36	2.2	98
105	GVHD prevention: an ounce is better than a pound. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, S17-26	4.7	7
104	First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1150-63	4.7	399
103	Improving outcomes in umbilical cord blood transplantation: state of the art. <i>Blood Reviews</i> , 2012 , 26, 241-6	11.1	29
102	Clinical benefit of response in chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1517-24	4.7	38
101	Risk factors for acute GVHD and survival after hematopoietic cell transplantation. <i>Blood</i> , 2012 , 119, 296-307	2.2	416

100	Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3202-8	2.2	115
99	Peripheral-blood stem cells versus bone marrow from unrelated donors. <i>New England Journal of Medicine</i> , 2012 , 367, 1487-96	59.2	620
98	Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. <i>Science Translational Medicine</i> , 2012 , 4, 117ra7	17.5	260
97	Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. <i>Therapeutic Advances in Hematology</i> , 2012 , 3, 253-65	5.7	32
96	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. <i>Blood</i> , 2012 , 120, 311-311	2.2	1
95	Gastrointestinal and Hepatic Involvement in Chronic Gvhd: An Analysis From the Chronic Gvhd Consortium. <i>Blood</i> , 2012 , 120, 1940-1940	2.2	
94	Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012 , 120, 1892-1892	2.2	
93	Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2012 , 120, 3069-3069	2.2	
92	Interleukin-2 and regulatory T cells in graft-versus-host disease. <i>New England Journal of Medicine</i> , 2011 , 365, 2055-66	59.2	787
91	Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 852-60	4.7	80
90	Generic immunosuppressants in hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 285-90	4.7	11
89	Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1196-204	4.7	51
88	Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1796-803	4.7	108
87	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. <i>Blood</i> , 2011 , 117, 4651-7	2.2	251
86	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. <i>Blood</i> , 2011 , 117, 6714-20	2.2	105
85	Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. <i>Blood</i> , 2011 , 118, 5021-30	2.2	34
84	Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. <i>Blood</i> , 2011 , 117, 2275-83	2.2	101
83	Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. <i>Blood</i> , 2011 , 118, 282-8	2.2	476

82	Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. <i>Blood</i> , 2011 , 118, 6691-7	2.2	153
81	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. <i>Blood</i> , 2011 , 118, 4242-9	2.2	169
80	Rituximab for prevention and treatment of graft-versus-host disease. <i>International Journal of Hematology</i> , 2011 , 93, 578-585	2.3	33
79	Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. <i>Journal of Clinical Oncology</i> , 2011 , 29, 511-78	2.2	21
78	A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS. <i>Blood</i> , 2011 , 118, 115-115	2.2	13
77	Does Iron Overload Really Matter in Stem Cell Transplantation?. <i>Blood</i> , 2011 , 118, 3029-3029	2.2	
76	A Disease and Stage Risk Grouping System for Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2011 , 118, 327-327	2.2	
75	Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2010 , 2010, 325-9	3.1	17
74	Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, S18-27	4.7	36
73	Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 792-800	4.7	68
72	Donor-derived second hematologic malignancies after cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1025-31	4.7	35
71	Prediction of veno-occlusive disease using biomarkers of endothelial injury. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1180-5	4.7	69
70	Patient selection for transplantation in the myelodysplastic syndromes. <i>Hematology/Oncology Clinics of North America</i> , 2010 , 24, 469-76	3.1	6
69	Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update. <i>Current Opinion in Hematology</i> , 2010 , 17, 500-4	3.3	35
68	Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. <i>Journal of Clinical Investigation</i> , 2010 , 120, 1479-93	15.9	175
67	Acute Graft Versus Host Disease: Prophylaxis 2010 , 565-576		
66	Reply to J. Mehta. <i>Journal of Clinical Oncology</i> , 2009 , 27, e139-e140	2.2	
65	Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. <i>British Journal of Haematology</i> , 2009 , 145, 816-24	4.5	59

64	High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. <i>Transfusion</i> , 2009 , 49, 995-1002	2.9	29
63	Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 844-50	4.7	47
62	Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1005-13	4.7	101
61	Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. <i>Blood</i> , 2009 , 113, 3865-74	2.2	236
60	Current and novel therapies in acute GVHD. <i>Best Practice and Research in Clinical Haematology</i> , 2008 , 21, 223-37	4.2	34
59	Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 197-207	4.7	82
58	Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 920-6	4.7	44
57	Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5767-74	2.2	92
56	Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2008 , 112, 4425-31	2.2	139
55	Novel drugs for the prevention and treatment of acute GVHD. <i>Current Pharmaceutical Design</i> , 2008 , 14, 1962-73	3.3	13
54	Stem Cell Sources for Allogeneic Transplantation 2008 , 225-244		
53	Development of CMV-SPECIFIC Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of NAI VE CD8+ T Cells. <i>Blood</i> , 2008 , 112, 1167-1167	2.2	
52	High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. <i>Clinical Cancer Research</i> , 2007 , 13, 6107-14	12.9	190
51	Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. <i>Blood</i> , 2007 , 109, 3108-14	2.2	163
50	Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. <i>Blood</i> , 2007 , 109, 4586-8	2.2	349
49	Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. <i>Blood</i> , 2007 , 110, 490-500	2.2	119
48	Double unrelated reduced-intensity umbilical cord blood transplantation in adults. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 82-9	4.7	264
47	Prior Therapy with Rituximab Correlates with Less Acute Graft-Versus-Host Disease and Better Survival in B-Cell Lymphoma Patients Who Received Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).. <i>Blood</i> , 2007 , 110, 1063-1063	2.2	1

46	Chronic GVHD Is Associated with a BAFF Driven BCR-Activated B Cell Repertoire.. <i>Blood</i> , 2007 , 110, 166-166		1
45	Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis.. <i>Blood</i> , 2007 , 110, 2016-2016	2.2	1
44	Tacrolimus and Sirolimus without Methotrexate as Acute GVHD Prophylaxis after Matched Related Donor Reduced Intensity Conditioning (RIC) Stem Cell Transplantation (SCT).. <i>Blood</i> , 2007 , 110, 3046-3046	2.2	1
43	Non-Myeloablative Allogeneic Transplantation for Hodgkin \bar{L} and Non-Hodgkin \bar{L} Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. <i>Blood</i> , 2007 , 110, 3041-3041	2.2	1
42	The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era. <i>Current Hematologic Malignancy Reports</i> , 2006 , 1, 160-7	4.4	1
41	Rituximab for steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2006 , 108, 756-62	2.2	378
40	Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 552-9	4.7	89
39	Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1047-55	4.7	161
38	Chronic graft-versus-host disease. <i>Current Opinion in Oncology</i> , 2006 , 18, 126-31	4.2	35
37	Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. <i>Blood</i> , 2006 , 108, 259-259	2.2	1
36	Risk of HHV6-Associated Post-Transplant Acute Limbic Encephalitis (PALE) after Umbilical Cord Blood Stem Cell Transplantation: A Cohort Analysis.. <i>Blood</i> , 2006 , 108, 2929-2929	2.2	1
35	Effects of Cord Blood Cell Subset Populations in the Development of the Dominant Cord Blood Unit in Non-Myeloablative Sequential Double Cord Blood Transplantation (DCBT).. <i>Blood</i> , 2006 , 108, 3148-3148	2.2	1
34	GM-CSF Secreting Leukemia Cell Vaccinations after Allogeneic Reduced-Intensity Peripheral Blood Stem Cell Transplantation (SCT) for Advanced Myelodysplastic Syndrome (MDS) or Refractory Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2006 , 108, 3680-3680	2.2	1
33	Prognostic Impact of Elevated Serum Ferritin in Patients Undergoing Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2006 , 108, 595-595	2.2	2
32	Costs of Complications after Allogeneic Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2006 , 108, 2971-2977		
31	Long-Term Outcome of Methotrexate-Free GVHD Prophylaxis Using Sirolimus and Tacrolimus in Matched Related (MRD) and Unrelated Donor (URD) Peripheral Blood Stem Cell Transplantation (PBSCT).. <i>Blood</i> , 2006 , 108, 757-757	2.2	
30	Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 383-8	4.7	89
29	Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 551-7	4.7	133

28	An overview of hematopoietic stem cell transplantation. <i>Clinics in Chest Medicine</i> , 2005 , 26, 517-27, v	5.3	23
27	Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. <i>Blood</i> , 2005 , 105, 1810-4	2.2	247
26	Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. <i>Blood</i> , 2005 , 105, 2973-8	2.2	315
25	HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2005 , 106, 835-835	2.2	3
24	Sirolimus and Tacrolimus without Methotrexate as Graft-vs.-Host Disease Prophylaxis after Matched, Unrelated Peripheral Blood Stem Cell Transplantation: Excellent GVHD Control with Low Transplant-Related Morbidity and Mortality.. <i>Blood</i> , 2005 , 106, 2051-2051	2.2	
23	Comparison of Methotrexate- Versus Sirolimus- Containing Graft-Versus-Host Disease Prophylaxis Regimens after Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2005 , 106, 1797-1797	2.2	
22	Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 328-36	4.7	124
21	Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. <i>Blood</i> , 2004 , 104, 1559-64	2.2	170
20	Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2004 , 104, 1224-6	2.2	128
19	A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. <i>Blood</i> , 2004 , 104, 579-85	2.2	535
18	Sirolimus and Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004 , 104, 1834-1834	2.2	1
17	Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.. <i>Blood</i> , 2004 , 104, 2251-2251	2.2	2
16	Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.. <i>Blood</i> , 2004 , 104, 351-351	2.2	3
15	Sirolimus, Tacrolimus and Reduced-Dose Methotrexate as Graft Versus Host Disease (GVHD) Prophylaxis after Non-Myeloablative Stem Cell Transplantation: Low Incidence of Acute GVHD Compared with Tacrolimus/Methotrexate or Cyclosporine/Prednisone.. <i>Blood</i> , 2004 , 104, 730-730	2.2	3
14	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. <i>Blood</i> , 2004 , 104, 1227-1227	2.2	
13	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. <i>Blood</i> , 2004 , 104, 185-185	2.2	
12	Allogeneic B Cell Response to H-Y Minor Histocompatibility Antigens after Donor Lymphocyte Infusion Correlates with Disease Response.. <i>Blood</i> , 2004 , 104, 296-296	2.2	
11	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. <i>Blood</i> , 2004 , 104, 300-300	2.2	

10	Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD.. <i>Blood</i> , 2004 , 104, 3317-3317	2.2	
9	Stem Cell Sources 2004 , 337-356		1
8	Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2003 , 102, 1578-82	2.2	270
7	Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. <i>Blood</i> , 2003 , 102, 1601-5	2.2	140
6	Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way. <i>Journal of Clinical Oncology</i> , 2002 , 20, 603-6	2.2	6
5	Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3685-91	2.2	359
4	Peripheral blood stem cells for allogeneic transplantation: a review. <i>Stem Cells</i> , 2001 , 19, 108-17	5.8	74
3	Choroidal metastases. Case 2: lung cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3358-9	2.2	2
2	Oral Complications in Hematopoietic Stem Cell Transplantation Survivorship172-182		
1	Manifestations and Treatment of Acute Graft-Versus-Host Disease1287-1303		10